VXRT:OTCMKTS
Vaxart Inc
US$ 0.43
arrow_downward
-0.02%(-0.000075) Siku 1
9 Okt, 16:00:00 GMT -4 · USD
search
Alama zote
| Alama | Bei | Tofauti | Tofauti ya asilimia |
|---|
insights_autoInatayarisha maarifa maarufu ya VXRT...
Fungua
US$ 0.44
Juu
US$ 0.45
Chini
US$ 0.43
Mtaji wa soko
106.59M
Wastani wa kiasi cha mauzo
elfu 265.13
Kiasi cha mauzo ya hisa
elfu 198.22
Uwiano wa bei ya hisa na mapato kwa kila hisa
2.66
Juu kwa wiki 52
US$ 0.84
Chini kwa wiki 52
US$ 0.30
EPS
US$ 0.16
Beta
1.05
Hisa za wawekezaji
242.84M
Idadi ya wafanyakazi
65
Fungua
US$ 0.44
Juu
US$ 0.45
Chini
US$ 0.43
Mtaji wa soko
106.59M
Wastani wa kiasi cha mauzo
elfu 265.13
Kiasi cha mauzo ya hisa
elfu 198.22
Uwiano wa bei ya hisa na mapato kwa kila hisa
2.66
Juu kwa wiki 52
US$ 0.84
Chini kwa wiki 52
US$ 0.30
EPS
US$ 0.16
Beta
1.05
Hisa za wawekezaji
242.84M
Idadi ya wafanyakazi
65
Habari
Kutoka kwenye vyanzo vya wavuti na washirika wa habari
Brave New Coin
·
dakika 26 zilizopita
Evernorth XRP Treasury Merger Brings 473 Million XRP to Nasdaq as XRPN Debuts October 12
Yahoo Finance
·
dakika 18 zilizopita
How to Beat a Choppy Market With 4 Steady Stocks
AOL.com
·
dakika 35 zilizopita
The S&P 500 Just Hit a Record High -- Here's How Much Higher It Can Climb, According to the Wall Street Consensus
24/7 Wall St.
·
saa 3 zilizopita
KLA Turned $1,000 Into $31,595 in a Decade, Crushing the S&P 500 by 8.7x
Wasifu
Vaxart, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of oral recombinant vaccines administered using temperature-stable tablets that can be stored and shipped without refrigeration, eliminating the need for needle injection. Its development programs for oral vaccine delivery include prophylactic, enteric-coated tablet vaccines for inhibiting norovirus, seasonal influenza, respiratory syncytial virus, and human papillomavirus. It was founded in 2004 by Sean Tucker. Originally incorporated as West Coast Biologicals, Inc. in California in 2004, the company later changed its name to Vaxart, Inc. in July 2007, after reincorporating in Delaware. A significant development in the company's history was the reverse merger with Aviragen Therapeutics, Inc. on February 13, 2018, which led to Vaxart becoming a wholly owned subsidiary of Aviragen. Post-merger, the company continued as Vaxart, Inc.
Vaxart's development portfolio includes a range of oral vaccines targeting infectious diseases such as norovirus, COVID-19, and seasonal influenza, as well as therapeutic vaccines like those targeting HPV. Wikipedia
Kuhusu Vaxart Inc
Afisa Mkuu Mtendaji (CEO)-
Wafanyakazi65
LilianzishwaMac 2004
Makao makuuSouth San Francisco, California, Marekani
Sekta-
Tovutivaxart.com